Loading
NASDAQHealthcareBiotechnology
Latest quote
$54.05
+$2.05 · +3.94%
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Previous close
$54.05
+$2.05 · +3.94%
After-hours
$54.05
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Day range
Current $54.05
52-week range
Current $54.05
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
53
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Day range
Current $54.05
52-week range
Current $54.05
Operating income
Net income
| Metric (CAD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 11.08M CAD | 1.18M CAD | 5M CAD | 12.18M CAD | 6.31M CAD |
| Selling, general, and administrative | 2.57M CAD | 1.45M CAD | 2.2M CAD | 2.55M CAD | 2.31M CAD |
| Operating expenses | 13.94M CAD | 2.82M CAD | 7.39M CAD | 14.98M CAD | 8.62M CAD |
| Interest income | 1.52M CAD | 30.13K CAD | — | — | — |
| Depreciation and amortization | 76.87K CAD | 73.36K CAD | 72.45K CAD | 6.04K CAD | 8.62M CAD |
| Operating income | −13.94M CAD | −2.82M CAD | −7.39M CAD | −14.98M CAD | −8.62M CAD |
| Net income | −12.23M CAD | −2.8M CAD | −7.37M CAD | −14.96M CAD | −8.65M CAD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$182.5
237.65% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 14, 2023 | 1:5 | — | — |
Effective Jul 14, 2023
1:5
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM9.72M0.01%78.27B USD0.19%$278.94+0.49%
iShares Russell 2000 Growth ETFIWO3.42M0.02%13.97B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO3.05M0.02%18B USD0.06%$112.66+0.50%
Vanguard U.S. Momentum Factor ETFVFMO2.03M0.10%1.9B USD0.13%$230.11+1.02%
AdvisorShares Psychedelics ETFPSIL2M4.27%46.85M USD1.84%$21.765+3.69%
iShares Micro-Cap ETFIWC1.15M0.09%1.32B USD0.60%$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG582.02K0.03%1.7B USD0.06%$260.49+0.91%
State Street SPDR S&P International Small Cap ETFGWX477.67K0.05%907.87M USD0.40%$45.56+0.93%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard U.S. Momentum Factor ETFVFMOAdvisorShares Psychedelics ETFPSILiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGState Street SPDR S&P International Small Cap ETFGWXAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
